Cell permeable, reversible and competitive inhibitor of CDK1/cyclin B (IC50=33nM), CDK2/cyclin A (IC50=33nM), CDK2/cyclin E (IC50=28nM) and CDK5/p35 (IC50=20nM).
Product Details
| Alternative Name: | (2R)-2-((6-((3-Amino-5-chlorophenyl)amino)-9-(1-methylethyl)-9H-purin-2-yl)amino)-3-methyl-1-butanol, NG-97 |
| |
| Formula: | C19H26N7OCl |
| |
| MW: | 403.9 |
| |
| CAS: | 220792-57-4 |
| |
| Purity: | ≥97% (HPLC) |
| |
| Identity: | Determined by NMR. |
| |
| Appearance: | White to brownish solid. |
| |
| Solubility: | Soluble in DMSO or methanol. |
| |
| Shipping: | Ambient Temperature |
| |
| Long Term Storage: | +4°C |
| |
| Handling: | Protect from light. Packaged under inert gas. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
M-phase regulation of the recruitment of mRNAs onto polysomes using the CDK1/cyclin B inhibitor aminopurvalanol: M. Le Breton, et al.; BBRC
306, 880 (2003),
Abstract;
A cyclin-dependent kinase inhibitor inducing cancer cell differentiation: biochemical identification using Xenopus egg extracts: G.R. Rosania, et al.; PNAS
96, 4797 (1999),
Abstract;
Full Text
Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors: Y.T. Chang, et al.; Chem. Biol.
6, 361 (1999),
Abstract;
